About us

Learn who we are and why we care

The Acanthamoeba Keratitis (AK) Eye Foundation was created to bring clarity, support, and reliable information to a community that has long been overlooked. Founded in 2022 by Juliette Vila Sinclair Spence after her own experience with AK, the foundation has grown into the first global organization dedicated solely to Acanthamoeba Keratitis.

Our Mission

Our mission is to bring the patient perspective forward — because only patients truly know what is needed, what has been missed, and what must change. What began as one patient’s advocacy has grown into a global effort to amplify the patient voice, improve understanding, and build a community of hope and connection. We collaborate with local patient advocates and partner foundations around the world to support awareness, education, and prevention of Acanthamoeba Keratitis.

Our Goals

ï‚¡

Awareness

Raising global awareness of AK and amplifying the patient perspective.



Education

To provide a hub of information about diagnosis, treatment and prevention.

ï’¾

support

To offer support to AK patients, family and friends accross the world.

Board

Juliette Vila Sinclair Spence

Founder & Chairwoman
Juliette experienced Acanthamoeba Keratitis (AK) firsthand and underwent an emergency corneal transplant, an event that shaped her commitment to raising awareness and supporting others affected by this rare disease. She leads with clarity, compassion, and a strong dedication to empowering patients through education and advocacy.

Marco Schraven

Treasurer & ICT Manager
Marco became committed to the Foundation’s mission after witnessing the impact of AK on his partner Juliette and their sons. With an ICT background in the financial sector, he brings technical expertise and clear operational insight, ensuring the Foundation’s resources and systems are managed with care and transparency.

Advisory Board

John KG Dart, MA, DM, FRCOphth

HONORARY ADVISORY BOARD
Professor John Dart from UCL Institute of Ophthalmology and Moorfields Eye Hospital NHS Foundation Trust, who serves on the AKEF Medical Advisory Board. As a clinical scientist, he is recognized for his collaborative work with other researchers in the laboratory. His research focuses on corneal infections, inflammatory diseases of the ocular surface, and translating these discoveries into clinical trials, with a specialization in Acanthamoeba Keratitis, Pemphigoid, and clinical trials.

Taher Eleiwa, MBBS, PhD

ADVISORY BOARD
Dr. Eleiwa earned his medical and surgical degrees at Benha University in Egypt, where he also served as faculty for over a decade. He earned his PhD in Cornea and External Eye diseases at the world-renowned Bascom Palmer Eye Institute in the USA. He currently practices as a corneal refractive and cataract surgeon at Magrabi Hospital in Saudi Arabia. Dr. Eleiwa specializes in severe corneal infections, corneal transplantation, and advanced anterior segment disease.

Thomas L. Steinemann, M.D.

ADVISORY BOARD
Professor Steinemann is a board-certified ophthalmologist specializing in cornea and cataract surgery. He serves as Clinical Professor at Case Western Reserve University and has been a teaching physician and Division Director at MetroHealth since 1999. His work focuses on ocular safety and contact lens policy, including co-leading efforts that secured U.S. federal law regulating all contact lenses as medical devices. He is a voting member of the FDA Ophthalmic Devices Panel and has received multiple AAO awards for his contributions to advocacy and patient safety.

Zachary Reynard, OD, FAAO

ADVISORY BOARD
Dr. Reynard graduated cum laude from the prestigious advanced scholars’ program at the Salus Pennsylvania College of Optometry. He went on to complete a residency in Cornea and Contact Lenses and a fellowship in Dry Eye Disease at the UAB School of Optometry. He has acted as a sub-investigator in multiple dry eye and contact lens clinical trials, and serves as medical editor for the digital publication EyeMedsNow. Dr. Reynard has treated thousands of patients with contact lens complications, including severe infections and corneal transplants.

Christopher A. Rice, PhD

ADVISORY BOARD
Dr. Rice is an Assistant Professor at Purdue University, USA. He graduated with a Ph.D. from the University of the West of Scotland in 2014 under the mentorship of Dr. Fiona Henriquez-Mui. His graduate studies were elucidating biochemical drug targets in Acanthamoeba. The Rice Research Group are focused on the discovery and development of anti-amoebic compounds and developing more rapid, sensitive, and specific diagnostics for diseases caused by pathogenic free-living amoebae.

Neil Lagali, PhD

ADVISORY BOARD
Neil Lagali is Full Professor of Experimental Ophthalmology at Linköping University in Sweden. He leads a team of researchers focusing on acquired and genetic corneal and diseases. He has a special interest in the diagnosis and epidemiology of infectious keratitis, and has been using in vivo confocal microscopy for over 20 years to diagnose Acanthamoeba keratitis cases. His recent interests in this area are in the refinement of diagnostics using artificial intelligence based tools and expert based consensus.

Katie Curro BSc. BA | Phd Candidate

ADVISORY BOARD
Katie Curro is an ophthalmic technician at Amsterdam UMC, specializing in diagnosing Acanthamoeba keratitis using in vivo confocal microscopy (IVCM). She led a landmark study in 2019 that characterized IVCM patterns before, during, and after treatment, resulting in a practical guide to help clinicians avoid misinterpretation. Katie continues to advance research into amoebic keratitis and in 2025 was awarded the Bayer Ophthalmology Prize for her work exploring non-Acanthamoeba species as potential causes.